Topic:

Clinical Trials

Latest Headlines

Latest Headlines

CytRx PhIIb cancer survival data fail to impress

CytRx released some unimpressive overall survival rates from its Phase IIb study of its aldoxorubicin compared with doxorubicin for soft tissue sarcoma.

As PhIII data looms, Nektar sets the stage for a big expansion

This is a big year for South San Francisco-based Nektar Therapeutics. And the company is making some big expansion plans, telling the local San Francisco Business Times that it has lined up a new lease on extra space as it sets the stage for adding up to 150 staffers.

Actavis, Richter tout new PhIII data for their tarnished schizophrenia drug

Fourteen months after the FDA rejected the new antipsychotic cariprazine, the developers say they have gathered together a new batch of late-stage data to demonstrate its effectiveness for schizophrenia, but the statement has done little to dispel the lingering doubts about this one-time blockbuster hopeful.

Singapore to detail trial of MicroVAX novel cancer vaccine

The National Cancer Centre Singapore will brief on the status of a first-in-human clinical trial using an adenovirus under a protocol endorsed by the U.S. Food and Drug Administration and Singapore's Health Sciences Authority, highlighting the wealthy city-state's push to be a leader in early stage clinical trials in Asia.

Arrowhead tanks after FDA reins in dosage on key hep B trial

Shares of Arrowhead Research took a beating Monday morning after the biotech revealed that the FDA had made a preliminary call on a partial clinical hold on a Phase IIb trial of its lead drug for hepatitis B.

Late-stage trials for Glaxo, Merck Ebola jabs could begin this month in West Africa

GlaxoSmithKline and tandem Merck and NewLink may have only recently ramped up development efforts for their Ebola vaccine candidates, but late-stage trials of the jabs in the affected countries are already on the horizon, the World Health Organization says.

Infinity scraps an arthritis program after lead drug fails PhII

Shares of Infinity Pharmaceuticals took a hit this morning after the company conceded that its mid-stage effort to advance its lead drug duvelisib for rheumatoid arthritis flopped on all three doses that were tried out. Infinity says that it will now scrub the RA program and stay focused on its late-stage deal with AbbVie to move duvelisib through the clinic for blood cancers.

Alkermes sees PhII promise for schizophrenia drug that doesn't pack on pounds

When Alkermes set out to develop ALKS 3831 for schizophrenia, it took a well-known antipsychotic--olanzapine--and combined it with a mu-opioid antagonist called samidorphan with an eye to controlling the disease without spurring the rapid weight gain that has bedeviled patients for years. Today, the company says it got the data it was looking for in Phase II and will now press ahead into a pivotal, late-stage program to see if they can replicate the results on a larger scale.

UPDATED: KaloBios tanks after scrapping another antibody following PhII flop

KB001-A, KaloBios Pharmaceuticals' antibody to treat lung infections in patients with cystic fibrosis, failed a Phase II study and is now joining the scrap heap started after KB003 failed Phase II for severe asthma last year.

Johnson & Johnson is third to bring Ebola vaccine to trials, but is it too late?

Johnson & Johnson started Phase I trials Tuesday for its Ebola vaccine, which its Janssen subsidiary developed in collaboration with Denmark's Bavarian Nordic. But does J&J's candidate come too late to catch up with its rivals and help combat the current epidemic?